AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23828145
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 (45 mg/day) and risedronate (2.5 mg/day or 17.5 mg/week)
Trial: 23828145
Drug: Risedronate alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate alone (2.5 mg/day or 17.5 mg/week)
Trial: 15208869
Drug: DMEM-therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMEM-therapy
Trial: 3307061
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of azathioprine, cyclosporine, and prednisone (+/- ALG)
Trial: 30489432
Drug: High-dose calfactant
RxNorm normalized name: Calfactant
DrugBank: Calfactant (DB06415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose calfactant (8.0 mg/ml)
Trial: 30489432
Drug: Low-dose calfactant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose calfactant (0.8 mg/ml)
Trial: 29523450
Drug: Additional early
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional early dose of measles vaccine (MV) 4 weeks after the third dose of DTP-containing Pentavalent vaccine and standard MV at 9 months
Trial: 29523450
Drug: Standard measles
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard measles vaccine (MV) at 9 months (control)
Trial: 29523450
Drug: Additional early
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional early dose of measles vaccine (MV) in children not exposed to an OPV campaign after enrolment
Trial: 24683472
Drug: Elevated plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated plasma levels of IL‐2 receptor alpha (IL‐2 RA)
Trial: 24683472
Drug: Elevated plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated plasma levels of tumour necrosis factor receptor type I
Trial: 22078632
Drug: 30 mcg
RxNorm normalized name: Avonex 30 MCG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mcg ethinyl estradiol (EE)/150 mcg levonorgestrel (LNG)
Trial: 22078632
Drug: 20 mcg
RxNorm normalized name: Caverject 20 MCG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mcg EE/100 mcg LNG
Trial: 22078632
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose pill (30 mcg EE/150 mcg LNG)
Trial: 22078632
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose pill (20 mcg EE/100 mcg LNG)
Trial: 19293263
Drug: dDAVP administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dDAVP administration
Trial: 17712402
Drug: Intradermal LIPO-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal LIPO-4 vaccine (0.1 ml, 100 microg of each peptide)
Trial: 17712402
Drug: Intramuscular LIPO-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular LIPO-4 vaccine (0.5 ml, 500 microg of each peptide)
Trial: 11125269
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% indomethacin solution
Trial: 15256991
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% fluorometholon acetate
Trial: 11280194
Drug: Oka-derived varicella
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain Injection [Varivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oka-derived varicella vaccines administered post-exposure within 3 days of rash onset
Trial: 9272811
Drug: Morphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (10 mg p.o.)
Trial: 9272811
Drug: Rifampin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (600 mg/day) with Morphine
Trial: 26580307
Drug: Light monotherapy
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light monotherapy (10,000-lux fluorescent white light box for 30 min/d in the early morning plus placebo pill)
Trial: 26580307
Drug: Fluoxetine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine monotherapy (inactive negative ion generator for 30 min/d plus fluoxetine hydrochloride, 20 mg/d)
Trial: 26580307
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (light and antidepressant)
Trial: 26580307
Drug: Placebo (inactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (inactive negative ion generator plus placebo pill)
Trial: 26342028
Drug: Rifampicin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin (600 mg) daily for 14 days
Trial: 26342028
Drug: Rifampicin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin (600 mg)/isoniazid (300 mg) daily for 14 days
Trial: 26342028
Drug: Rifampicin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin (600 mg)/isoniazid (300 mg) after washout
Trial: 26342028
Drug: Rifampicin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin (600 mg) after washout
Trial: 20683270
Drug: EVG/COBI 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVG/COBI 150 mg/FTC/TDF
Trial: 16786387
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (same osteoporosis drug therapy)
Trial: 16786387
Drug: New traumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New traumatic vertebral body fractures (managed by fixateur interne alone or combination with kyphoplasty)
Trial: 11998139
Drug: Behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior therapy methods for urinary incontinence
Trial: 1524963
Drug: Low dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage of pyridostigmine (30 mg three times daily)
Trial: 1524963
Drug: Transdermal hyoscine
RxNorm normalized name: HYOSCINE HYDROBROMIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal hyoscine patches
Trial: 3890160
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with hip joint distension arthrography
Trial: 20185416
Drug: Medication plus
RxNorm normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication plus 10 sessions of biofeedback-assisted relaxation training (BART)
Trial: 20185416
Drug: Standardized medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized medication treatment
Trial: 17919380
Drug: HTEA (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTEA (high thoracic epidural anesthesia) with 0.5% lidocaine 3 ‐ 5 ml every two hours for one month
Trial: 17919380
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine medication)
Trial: 12173196
Drug: Diclofenac (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (50 mg orally every 8 h the day before surgery and 75 mg i.m. every 12 h on the day of surgery)
Trial: 9443711
Drug: Tiagabine 32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine 32 mg daily
Trial: 9443711
Drug: Tiagabine 56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine 56 mg daily
Trial: 9443711
Drug: Tiagabine 16
RxNorm normalized name: tiaGABine 16 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine 16 mg daily
Trial: 2379255
Drug: Simultaneous inoculation
RxNorm normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous inoculation with DPT and BCG vaccines
Trial: 30820923
Drug: Solution based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution based on autonomy
Trial: 30820923
Drug: Solution based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution based on coercion
Trial: 30820923
Drug: Solution based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution based on reciprocity
Trial: 23796582
Drug: Fidaxomicin 200
RxNorm normalized name: fidaxomicin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fidaxomicin 200 mg b.i.d. for 10 days
Trial: 23796582
Drug: Vancomycin 125
RxNorm normalized name: vancomycin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 125 mg q.i.d. for 10 days
Trial: 21835296
Drug: Combination antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVE COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antihypertensive therapy (thiazide and potassium-sparing diuretic; thiazide and angiotensin-converting enzyme inhibitor)
Trial: 21835296
Drug: Single-drug initial
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single-drug initial therapy
Trial: 19843489
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of valsartan 160 mg
Trial: 19843489
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of valsartan 160 mg
Trial: 15212193
Drug: Drotaverine capsule
RxNorm normalized name: drotaverin
DrugBank: Drotaverine (DB06751)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drotaverine capsule preparation (20 mg Droxa mite)
Trial: 15212193
Drug: Reference tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference tablet preparation
Trial: 9059680
Drug: Cyclosporine at
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine at 3 mg/kg/day
Trial: 9059680
Drug: Topical betamethasone-17,21-dipropionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betamethasone-17,21-dipropionate
Trial: 3527592
Drug: Oral 1
RxNorm normalized name: SYRINGE,ORAL 1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 1 g Neomycin plus 0.25 g Metronidazole t.i.d. on the last preoperative day
Trial: 3527592
Drug: Intravenous single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous single dose 5 g Mezlocillin plus 0.5 g Metronidazole
Trial: 28830491
Drug: BioLex®-GLM (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BioLex®-GLM (600 mg daily)
Trial: 16564374
Drug: Multilevel surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multilevel surgical protocol including uvulaflap, tonsillectomy, hyoid suspension, and radiofrequency treatment of the tongue base (group A)
Trial: 16564374
Drug: Surgery without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surgery without hyoid suspension (group B)
Trial: 9357885
Drug: Dexmedetomidine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine at concentrations of 0.3 ng/ml and 0.6 ng/ml
Trial: 8096945
Drug: Leukotriene LTE4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukotriene LTE4 inhalation
Trial: 3803701
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate spray (2.5 mg, 2 squirts, administered 2 min before testing)
Trial: 29571817
Drug: mOPV2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mOPV2 doses at 1 week interval (n=191)
Trial: 29571817
Drug: mOPV2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mOPV2 doses at 2 weeks interval (n=191)
Trial: 29571817
Drug: mOPV2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mOPV2 doses at 4 weeks interval (n=188)
Trial: 29571817
Drug: mOPV2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mOPV2 doses at 4 weeks interval plus IPV (n=190)
Trial: 16626384
Drug: Skin-lightening gel
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Skin-lightening gel with ultrasound
Trial: 16626384
Drug: Skin-lightening gel
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Skin-lightening gel treatment
Trial: 10024108
Drug: Soybean oil
RxNorm normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean oil emulsion + 1.8 g/day EPA
Trial: 2279535
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PGI2 and PGE1
Trial: 2279535
Drug: Second infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second infusion of the same compound
Trial: 25131348
Drug: Higher fiber
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher fiber intake (8.3 g/day increase)
Trial: 17270513
Drug: Twice-weekly supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly supervised pulmonary rehabilitation (2 sessions/week)
Trial: 17270513
Drug: Once-weekly supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly supervised pulmonary rehabilitation (1 session/week)
Trial: 12174159
Drug: Methenamine hippurate
RxNorm normalized name: Methenamine Hippurate
DrugBank: Methenamine (DB06799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methenamine hippurate (1 g Hiprex, twice daily for 5 days)
Trial: 9869506
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg, t.d.s.)
Trial: 9869506
Drug: Lisinopril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10 mg, o.d.)
Trial: 7989628
Drug: 5 percent
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Lidocaine 5 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 percent EMLA cream
Trial: 7989628
Drug: 5 percent
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Lidocaine 5 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 percent lidocaine ointment
Trial: 25697763
Drug: Cryo-ultrasound (cryo-US)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryo-ultrasound (cryo-US) therapy
Trial: 23427839
Drug: Group treatment
RxNorm normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group treatment using manualized hypnosis
Trial: 23427839
Drug: Individual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual treatment using manualized hypnosis
Trial: 16834789
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate (50 mg kg‐1 in 100 mL of isotonic saline over 20 min)
Trial: 9305483
Drug: Oral elemental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral elemental diet (Peptamen, Clintec, USA) for 2 weeks
Trial: 2572741
Drug: Oleic acid
RxNorm normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oleic acid (3.5 g)
Trial: 2572741
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil (30 g, predominantly diunsaturated)
Trial: 2572741
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (30 g, predominantly monounsaturated)
Trial: 2572741
Drug: Suet (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suet (30 g, predominantly saturated)
Trial: 30711603
Drug: Conventional method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional method (C) - custom tray with impression compound and silicone
Trial: 28551715
Drug: Methylphenidate (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (60 mg)
Trial: 12433007
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of exercise and medication
Trial: 30718126
Drug: Interval cytoreductive
RxNorm normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interval cytoreductive surgery (ICS) + hyperthermic intraperitoneal chemotherapy (HIPEC)
Trial: 23257667
Drug: Bright Futures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright Futures Oral Health curriculum
Trial: 19351801
Drug: Caffeine plus
RxNorm normalized name: Caffeine Plus Green Tea Extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine plus zolpidem (10 mg)
Trial: 19351801
Drug: Caffeine plus
RxNorm normalized name: Caffeine Plus Green Tea Extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine plus trazodone (100 mg)
Trial: 15229817
Drug: Aprotinin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (1 Mio KIE) administered at the latest 15 min before delivery
Trial: 2952619
Drug: Vasopressin derivative
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressin derivative (daily for 10 days)
Trial: 2952619
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of vasopressin derivative
Trial: 2952619
Drug: Vasopressin treatment
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressin treatment (three times weekly for 6 weeks in rats)
Trial: 8649563
Drug: rIFNbeta (unspecified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFNbeta (unspecified dose)
Trial: 31401049
Drug: IV ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketamine (7 mg kg‐1) and IV midazolam (0.25 mg kg‐1)
Trial: 31401049
Drug: Oral fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fluconazole (5 mg kg‐1) administered 12 and 24 hours prior to ketamine-midazolam
Trial: 22337532
Drug: VDW chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VDW chemotherapy data for trastuzumab
Trial: 22337532
Drug: VDW chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VDW chemotherapy data for anthracyclines
Trial: 22337532
Drug: VDW chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VDW chemotherapy data for other chemotherapy
Trial: 22337532
Drug: VDW mean
RxNorm normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VDW mean doses for trastuzumab
Trial: 22337532
Drug: VDW mean
RxNorm normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VDW mean doses for anthracyclines
Trial: 19818174
Drug: Coartem Dispersible
RxNorm normalized name: Coartem
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coartem Dispersible (dispersible formulation of artemether/lumefantrine)
Trial: 19818174
Drug: Crushed AL
RxNorm normalized name: AL-034
DrugBank: AL-034 (DB17471)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed AL tablets (control)
Trial: 9750527
Drug: Neoadjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant hormonal therapy for 2 years
Trial: 9750527
Drug: Neoadjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant hormonal therapy for 2 years (stage C cancer)
Trial: 7825970
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of 5FU
Trial: 3339175
Drug: Superior vena
RxNorm normalized name: Sus scrofa superior gastric plexus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superior vena cava spring-left ventricular patch electrode system (6.7 cm2 anode, 13.5 cm2 cathode)
Trial: 3339175
Drug: Spring-patch system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spring-patch system
Trial: 20203627
Drug: 6 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g/day of flavanol-rich dark chocolate
Trial: 20203627
Drug: 25 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g/day of flavanol-rich dark chocolate
Trial: 10326149
Drug: New thrombolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New thrombolytic agents (including reteplase, TNK-t-PA, lanoteplase)
Trial: 10326149
Drug: Thrombolytics combined
RxNorm normalized name: THROMBOLYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytics combined with new glycoprotein IIb/IIIa platelet inhibitors and anti-thrombin agents
Trial: 1725033
Drug: Ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 5 mg/day (treatment A)
Trial: 1725033
Drug: Ramipril 1.25
RxNorm normalized name: ramipril 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 1.25 mg/day (treatment B)